189 related articles for article (PubMed ID: 25011986)
1. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
[TBL] [Abstract][Full Text] [Related]
2. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
[TBL] [Abstract][Full Text] [Related]
3. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
4. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
[TBL] [Abstract][Full Text] [Related]
6. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
7. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
[TBL] [Abstract][Full Text] [Related]
8. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
[TBL] [Abstract][Full Text] [Related]
9. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Jacob L; Dreher M; Kostev K; Hadji P
Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
[TBL] [Abstract][Full Text] [Related]
10. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
11. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
12. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.
Wong M; Wan X; Ruff V; Krohn K; Taylor K
Osteoporos Int; 2012 Apr; 23(4):1445-52. PubMed ID: 21769662
[TBL] [Abstract][Full Text] [Related]
13. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
Oswald AJ; Berg J; Milne G; Ralston SH
Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
[TBL] [Abstract][Full Text] [Related]
15. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
17. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
[TBL] [Abstract][Full Text] [Related]
18. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
[TBL] [Abstract][Full Text] [Related]
19. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects of Teriparatide Followed by Antiresorptive Therapy on Clinical Outcomes in Patients with Severe Spinal Osteoporosis.
Oswald AJ; Berg K; Ralston SH; Riches PL
Calcif Tissue Int; 2019 Aug; 105(2):148-155. PubMed ID: 31115640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
